

Number of shares and votes in Calliditas Therapeutics

During July, the number of shares and votes in Calliditas Therapeutics AB (publ) (the “Company”) has increased due to the issue of 1,970,000 new shares that the Company carried out pursuant to the utilization of the over-allotment option that the Company granted in order to cover any over-allotment in the offering of shares in connection with the listing of the Company’s shares on Nasdaq Stockholm. As of July 31, 2018, the number of shares and votes in the Company is 35,202,347.

For further information, please contact:

Renée Aguiar-Lucander, CEO at Calliditas

Email: renee.lucander@calliditas.com

Telephone: +46 722 52 10 06

Mikael Widell, Head of Communications at Calliditas

Email: mikael.widell@calliditas.com

Telephone: +46 703 11 99 60

The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on July 31, 2018.

About Calliditas Therapeutics

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. Visit www.calliditas.com for further information.